Head to Head Contrast: Zenas Biopharma (ZBIO) & Its Rivals

Zenas Biopharma (NASDAQ:ZBIO) is one of 422 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Zenas Biopharma to related businesses based on the strength of its dividends, institutional ownership, earnings, valuation, analyst recommendations, profitability and risk.

Dividends

Zenas Biopharma pays an annual dividend of $0.05 per share and has a dividend yield of 0.6%. Zenas Biopharma pays out -1.4% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 4.5% and pay out 116.1% of their earnings in the form of a dividend.

Earnings and Valuation

This table compares Zenas Biopharma and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zenas Biopharma	$5.00 million	N/A	-2.35
Zenas Biopharma Competitors	$154.14 million	-$11.26 million	-56.28

Zenas Biopharma’s competitors have higher revenue, but lower earnings than Zenas Biopharma. Zenas Biopharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Zenas Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas Biopharma	N/A	N/A	N/A
Zenas Biopharma Competitors	-14,682.20%	39.10%	-32.41%

Insider & Institutional Ownership

29.3% of shares of all “Biotechnology” companies are owned by institutional investors. 22.5% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Zenas Biopharma and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas Biopharma	0	0	2	0	3.00
Zenas Biopharma Competitors	836	2280	4733	57	2.51

Zenas Biopharma presently has a consensus price target of $40.00, suggesting a potential upside of 380.19%. As a group, “Biotechnology” companies have a potential upside of 61.54%. Given Zenas Biopharma’s stronger consensus rating and higher probable upside, equities analysts plainly believe Zenas Biopharma is more favorable than its competitors.

Summary

Zenas Biopharma beats its competitors on 7 of the 13 factors compared.

About Zenas Biopharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.